The c4c project aims to develop a Pan European Paediatric Clinical Trial Network. As part of the development of the c4c network we are creating a series of podcasts centred on the work of the network.

The how and why of COVID-19 vaccines for children

c4c has launched a new podcast series – each month we will be publishing a podcast on topical issues around c4c and paediatric research.

For our first podcast, we focus on Covid-19 vaccines for children and young people, with Dr Federico Martinòn-Torres providing insights about paediatric clinical trials.

Topics that are discussed during the podcast:

  • The reason behind the lack of paediatric clinical trials for COVID-19 vaccine
  • The necessity of having COVID-19 vaccines for children on the herd immunity as well as on the individual side
  • Social inequalities linked to school closures
  • The current challenges in paediatric clinical trials for COVID-19 vaccine

You can view the podcast directly on our podcast platform here.

cASPerCF: Proof of viability studies to test the c4c network

The c4c network is carrying out a selection of Proof of Viability (PoV) trials from both academia and industry to test its functionalities, and to build a more effective and sustainable network for the future. c4c have released two new podcasts about cASPerCF, one of the first non-industry PoV trials to test the network’s infrastructure. The cASPerCF trial aims to find the right dose of posaconazole to treat children and young people with Cystic Fibrosis and Aspergillus infection.

In the first podcast, we have Prof Adilia Warris providing an overview of the cASPerCF trial and how it is supported by the c4c network. Listen here.

In the second podcast, we have Jacob Bradbury providing a short overview on what Cystic Fibrosis is, how it affects children and what the aims of the trial are. Listen here.

Insights from c4c’s expert groups

In this podcast episode, we are joined by Professor Franz Schaefer, Head of Pediatric Nephrology at Heidelberg University Hospital, and Saskia de Wildt, Professor of Clinical Pharmacology and pediatric intensivist at Radboud University & Erasmus MC Sophia Children’s Hospital.

Franz and Saskia are both involved in the c4c methodology experts’ groups, that bring together experts in different fields intending to advise pharmaceutical companies or academic trials during a paediatric clinical trial.

How was this initiative set up? How do patients participate in these groups as well? What requests have been solved until now?

Listen to this new episode to find out –

The best kept secret of science communication

Why is Science communication essential nowadays, especially for an European Network as conect4children? How to efficiently communicate science? How to overcome the challenges around fake news?

In our new podcast episode, Claudio Fracasso and Lindsey Hunter, the c4c leads for communication, dissemination, exploitation, impact assessment, talk about the importance of science communication and its central role in c4c.

Topics discussed during the podcast include:

  • why it’s important to communicate science, especially for c4c
  • how communicating science is not a one-way process
  • the future devolvement of science communication
  • using social media
  • coping with ‘fake news’ and anti-science sentiments
  • c4c challenges of communicating science around paediatric clinical trials
  • best communication practices

You can listen directly to our podcast here.

What’s the KD-CAAP trial? (for patients)

Kawasaki disease is an acute febrile illness of unknown cause that primarily affects children younger than 5 years of age.

The clinical trial “KD-CAAP” studies the effectiveness of adding a new element to the standard treatment for this disease. What are the hopes for Kawasaki disease treatment and patients?

Listen to our podcast with Prof. Paul Brogan, joined chief investigator of the KD-CAAP trial, that will explain you what Kawasaki disease is, why KD-CAAP trial is important, and what are the perspectives around this disease that affects mostly children. Link is: 

KD-CAAP trial (for professionals)

Kawasaki disease, also known as Kawasaki syndrome, is an acute febrile illness of unknown cause that primarily affects children younger than 5 years of age.

KD-CAAP proof of viability study assesses the effectiveness of adding steroids to standard treatment in children with Kawasaki Disease.

Why is it important to improve paediatric patient’s lives? How is c4c supporting this study?

Listen to our podcast with Prof. Paul Brogan, joined chief investigator of the KD-CAAP trial! Link is: